Uric acid crystallization

Uric acid crystallization refers to the precipitation and formation of uric acid or monosodium urate crystals from supersaturated body fluids, particularly in urine (causing kidney stones) and synovial fluid (causing gout)[4][1]. The crystallization process is heavily influenced by local concentration, temperature, pH, presence of nucleating surfaces (such as collagen or damaged cartilage), and various promoting and inhibiting proteins found in body fluids[1][2][5]. These crystals are highly pro-inflammatory, stimulating immune responses through mechanisms such as NLRP3 inflammasome activation that leads to interleukin-1β release and acute inflammatory attacks in affected tissues[3][6]. While uric acid crystallization itself is not a classical therapeutic target, controlling serum urate levels to prevent crystal formation is the mainstay of therapy for gout and uric acid stone disease[4][1].

Other names

Uric acid crystal formationMonosodium urate crystallizationMSU crystallization

Inhibition of uric acid synthesis (xanthine oxidase inhibitors: allopurinol, febuxostat); Enhancement of uric acid excretion (uricosuric agents: probenecid, lesinurad); Enzymatic degradation of uric acid (pegloticase). (The above mechanisms alter uric acid levels to prevent crystal formation; there are no drugs that directly target the crystallization process itself)[4][1].